Blue banner that says "Press Release"

Approval of Two New Prostate Cancer Drugs Gives Patients and Families Hope

FOR IMMEDIATE RELEASE

MEDIA CONTACT:
Ilana Ostrin
202-657-2249
ilana@zerocancer.org

 

Approval of Two New Prostate Cancer Drugs Gives Patients and Families Hope

U.S. Department of Health and Human Services FDA Building

In the span of a week, the FDA permits two new drugs for advanced prostate cancer patients to move to market

Washington, D.C., May 20, 2020 -- It’s a thrill for prostate cancer advocates when a new treatment moves from the research bench to the patient’s bedside. When this occurs, hope ripples across the cancer community. Lightning struck twice this week for the prostate cancer community, as the FDA approved olaparib (LYNPARZA) for patients with metastatic castration-resistant prostate cancer (mCRPC). The news comes only days after the agency approved another drug (Rubraca) that is also targeted to mCRPC patients.

“This news gives patients double the hope as we now have more novel solutions for fighting advanced prostate cancer,” Jamie Bearse, ZERO’s CEO, said. “Now patients have the option of another completely new pharmacological treatment, which has greatly improved outcomes for patients in studies. This is a great example of how we can target treatments based on precision medicine results. It’s exciting to think that future similar advancements will continue to develop and progress to battle prostate cancer.”

Olaparib is targeted to patients who have deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations and have progressed following prior treatment with a new hormonal agent. LYNPARZA is jointly developed and commercialized by AstraZeneca and Merck

For more on olaparib and its study findings, click here.

                                                                      


About ZERO Prostate Cancer

ZERO Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted. ZERO advances research, provides support, and creates solutions to achieve health equity to meet the most critical needs of our community. From early detection to survivorship, ZERO is the premier resource for prostate cancer patients and their families to access comprehensive support, make meaningful connections, and take action to save lives. Our dedicated national and chapter staff is joined with a growing team of passionate volunteer champions to increase advocacy, awareness, and community engagement to ZERO out prostate cancer. ZERO is recognized with four out of four stars by Charity Navigator and accredited by the Better Business Bureau. ZERO spends more on programs than any other prostate cancer charity, dedicating 85 cents of every dollar to support, education, and research.

Share